Vaishali Pharma Board Approves Increase in Authorized Share Capital
The Board of Directors of Vaishali Pharma Limited, in a meeting held on July 2, 2026, reviewed and approved several key corporate actions related to the company’s capital structure. The primary decision involved an increase in the authorized share capital, which is now subject to member approval via a postal ballot.The Board considered and sanctioned the shift in the Authorized Share Capital from its previous structure to a new level. The details of this change are as follows:
| Aspect | Previous Status | New Status |
|---|---|---|
| Authorized Capital | INR 27,00,00,000 | INR 29,00,00,000 |
| Total Shares | 13,50,00,000 Equity Shares | 14,50,00,000 Equity Shares |
| Face Value per Share | INR 2/- | INR 2/- |
Following the approval of this capital increase by the members, the Memorandum of Association will require consequential alterations. The Board approved the draft Postal Ballot Notice to seek members' consent for both the increased Authorized Share Capital and the necessary changes to the company’s Memorandum of Association. Furthermore, the Company Secretary was authorized to undertake all required actions and modifications concerning the notice.
In addition to these decisions, the Board meeting also addressed a proposal regarding the Issue and Allotment of 61,23,000 equity shares at INR 2/- each, which was deferred for future consideration.
VAISHALI Stock Price Movement
Vaishali Pharma Limited saw its stock shed 0.40% in trading, settling today at ₹7.32 after closing lower from yesterday’s close of ₹7.41. The equity traded a volume of 33,101 shares during the session, which settled between an intraday low of ₹7.21 and a high of ₹7.5.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.